Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manganese Chloride + Anti-PD-1 in Advanced Solid Tumors and Lymphomas
NCT03991559Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of manganese chloride in solid tumor and lymphoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Number of Subjects with treatment-related adverse events at 6 months and Number of subjects with specific Manganese-related adverse events at 6 months. Status: unknown.
02
Drugs
manganese chloride
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03991559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991559.